Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced

Winners of the second annual Lyfebulb-Helsinn Innovation Summit...

Helsinn initiates two new global Phase III studies with anamorelin

▪ Helsinn committed to anamorelin which is being evaluated...

Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology

The Award recognizes Patient Entrepreneurs’ innovations for...